Anne Wojcicki, 23andMe CEO (Photographer: Jordan Vonderhaar/Bloomberg via Getty Images)

August 9, 2024 12:07 PM EDTUpdated August 12, 02:10 PM

23andMe trades drug discovery for GLP-1 weight loss prescriptions

Shelby Livingston

Senior health tech reporter

23andMe is shutting down its internal drug discovery group and getting into prescription weight loss drugs in an effort to turn the struggling consumer genetic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

23andMe trades drug discovery for GLP-1 weight loss prescriptions

Shelby Livingston

Senior health tech reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

House passes Biosecure Act, sending Chinese biotech ban to Senate

AstraZeneca, Gilead detail TROP2 ADC data in lung cancer as they search for new ways forward

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

Lilly again hires from within for CFO post, elevating 23-year company veteran

Terns’ oral GLP-1 passes Phase 1 test with promising weight loss after one month

Summit's Phase 3 data back up biotech's boasts of beating Keytruda in lung cancer

23andMe trades drug dis­cov­ery for GLP-1 weight loss pre­scrip­tions

Senior health tech reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

23andMe trades drug discovery for GLP-1 weight loss prescriptions